The percentage of CD69+ NK cells fromhealthy donors was also more than refractory/relapsed DLBCLpatients and responsive DLBCL patients in the presence plasma-derived exosome of refractory/relapsed DLBCL patients plusIL-2/IL-15 (P=0.018 and P=0.034, respectively, ANOVA test). The gene discussed is CD69; the disease is diffuse large B-cell lymphoma.